🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Haider Mahdi

Magee-Womens Hospital

ORCID: 0000-0002-6343-5314

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity”.

Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3659

N/A

1.7DataRank · unranked

34 citations

Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana +11 more

Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-003833

N/A

0.835DataRank · unranked

23 citations

Germán Corredor, Kaustav Bera, Patrick Leo, Pingfu Fu, Paula Toro +5 more

Association of neighborhood social vulnerability with ovarian cancer survival

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.10.030

N/A

0.312DataRank · unranked

7 citations

Esther Elishaev, Riyue Bao, Emily C. O’Brien, Kaitlyn Dinkins, Jessica Berger +17 more

A core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multi-cancer prognosis

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.04.20.537691

N/A

0.281DataRank · unranked

3 citations

Harshita Kumar, Kristin Aldridge, Stevie Rieger, Ethan Jiang, E. Ricky Chan +4 more

Computational features of TIL architecture are differentially prognostic of uterine cancer between African and Caucasian American women.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5585

N/A

0.269DataRank · unranked

5 citations

Pingfu Fu, Haider Mahdi, Anant Madabhushi, Sepideh Azarianpour Esfahani

An LC–MS/MS method for determination of the bromodomain inhibitor ZEN-3694 and its metabolite ZEN-3791 in human plasma

Bioanalysis(2024)10.4155/bio-2023-0252

N/A

0.104DataRank · unranked

1 citations

Haider Mahdi, Richard Piekarz, Jan H. Beumer, Timothy W. Synold, Ye Feng

Computational pathology identifies immune-mediated collagen disruption to predict clinical outcomes in gynecologic malignancies

Communications Medicine(2024)10.1038/s43856-023-00428-0

N/A

0DataRank · unranked

17 citations

Sirvan Khalighi, Deepak Babu, Haojia Li, Sepideh Azarianpour, Germán Corredor +9 more

Computerized features of spatial arrangement of tumor-infiltrating lymphocytes from H&E images predicts survival and response to checkpoint inhibitors in gynecologic cancers.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6074

N/A

0DataRank · unranked

2 citations

Germán Corredor, Kaustav Bera, Pingfu Fu, Amy Joehlin‐Price, Haider Mahdi +2 more

All-cause mortality and neighborhood social vulnerability among women with ovarian cancer

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.02.014

N/A

0DataRank · unranked

5 citations

Lauren Borho, Esther Elishaev, Jessica Berger, M.M. Boisen, John T. Comerci +12 more

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition

npj Precision Oncology(2021)10.1038/s41698-021-00242-8

N/A

0DataRank · unranked

56 citations

Ahmed Soliman, Amy Joehlin‐Price, Peter G. Rose, Anda Vlad, Robert P. Edwards +2 more

Clinical factors associated with failed sentinel lymph node mapping in endometrial cancer

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.101080

N/A

0DataRank · unranked

13 citations

Alyssa Wield, Brigid Mumford, Isabel Janmey, Li Wang, Philip J. Grosse +13 more

SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4179

N/A

0DataRank · unranked

5 citations

Edward Mayerson, E. Gabriela Chiorean, Earle F. Burgess, Elizabeth M. Swisher, Carl M. Gay +9 more

Data from Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

(2023)10.1158/1078-0432.c.6532676

N/A

0DataRank · unranked

0 citations

Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana +11 more

Data from Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

(2023)10.1158/1078-0432.c.6532676.v1

N/A

0DataRank · unranked

0 citations

Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana +11 more